利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.035 秒)

    Treatment of inflammatory disorders
    1.
    发明申请
    Treatment of inflammatory disorders 审中-公开

    公开(公告)号：US20060276440A1

    公开(公告)日：2006-12-07

    申请号：US11325615

    申请日：2006-01-03

    申请人： Wenqian An ,  Jun Park ,  Mehran Khodadoust ,  Hans-Jurgen Hess ,  Md. Hussom

    发明人： Wenqian An ,  Jun Park ,  Mehran Khodadoust ,  Hans-Jurgen Hess ,  Md. Hussom

    IPC分类号： A61K31/57 ,  A61K31/517 ,  A61K31/428 ,  A61K31/366 ,  A61K31/203

    CPC分类号： A61K31/203 ,  A61K31/05 ,  A61K31/09 ,  A61K31/165 ,  A61K31/19 ,  A61K31/343 ,  A61K31/365 ,  A61K31/366 ,  A61K31/37 ,  A61K31/415 ,  A61K31/428 ,  A61K31/498 ,  A61K31/517 ,  A61K31/56 ,  A61K31/57 ,  C07F9/12

    摘要： Methods of treating an inflammatory disorder include administering an effective amount of a compound represented by Structural Formula (I): Ring A is optionally substituted, contains zero, one, two, or three double bonds, and is optionally fused to an aliphatic, aryl or heteroaryl ring; X is an optionally substituted 1 to 3 carbon aliphatic chain that is optionally fused to a monocyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring, wherein one or two carbons in X are optionally replaced with —O—, —S—, or —NRe—; Y is carbon or nitrogen; R1 and R2 are independently —H, —OH, —CN, —NO2, —NRfRg, halogen, optionally substituted alkyl, or optionally substituted alkoxy; or R1 and R2 together link the carbons to which they are bonded with a bond, —O—, —S—, or —NRh—; R3 and R4 are independently —H, —OH, —CN, —NO2, —NRiRj, halogen, optionally substituted alkyl, or optionally substituted alkoxy, or R4 is ═O; or R3 and R4, taken together with the atoms to which they are bonded, form a monocyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring that is optionally fused to a monocyclic or bicyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring; Re-Rj are independently —H or optionally substituted alkyl; and each of the OSM signaling inhibitor compounds has at least one hydrogen atom bonded to an oxygen, nitrogen, or sulfur atom. The OSM signaling inhibitor compounds also include pharmaceutically acceptable salt or solvates of the compounds represented by Structural Formula (I).

    Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders
    3.
    发明申请
    Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders 审中-公开
    低氧诱导因子-1的调节剂及相关用途治疗眼部疾病

    公开(公告)号：US20110076278A1

    公开(公告)日：2011-03-31

    申请号：US11989362

    申请日：2006-08-01

    申请人： Mehran Khodadoust

    发明人： Mehran Khodadoust

    IPC分类号： A61K31/7048 ,  A61K39/395 ,  A61K31/58 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P37/06

    CPC分类号： A61K31/704 ,  A61K31/7048 ,  A61K39/395 ,  A61K2300/00

    摘要： Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor-1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigenin, digoxin, lanatoside C, strophantin K, uzarigenin, ouabain and proscillaridin. In some embodiments the ocular disorder is characterized by ischmia.

    摘要翻译： 使用类固醇治疗眼部疾病的方法调节由缺氧诱导因子-1（HIF-1）介导的局部和全身缺氧事件的作用。 可用作HIF-1调节剂的类固醇包括蟾蜍灵，洋地黄毒苷，地高辛，藜芦苷C，维生素K，紫苏碱，哇巴因和前列腺素。 在一些实施方案中，眼部疾病的特征在于异位症。

    Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
    5.
    发明申请
    Pancreatic cancer treatment using Na+/K+ ATPase inhibitors 审中-公开
    使用Na + / K + ATP酶抑制剂进行胰腺癌治疗

    公开(公告)号：US20060135442A1

    公开(公告)日：2006-06-22

    申请号：US11219638

    申请日：2005-09-02

    申请人： Mehran Khodadoust ,  Ajay Sharma

    发明人： Mehran Khodadoust ,  Ajay Sharma

    IPC分类号： A61K31/704

    CPC分类号： A61K31/704

    摘要： The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers.

    摘要翻译： 本发明的试剂，药物制剂，试剂盒和方法提供了治疗胰腺癌的新方法。 本发明提供了单独或与其它组合使用的Na + + / K + + / - ATP酶抑制剂，例如强心苷（例如哇巴因和前列腺素等） 用于治疗胰腺癌的标准治疗剂（化疗或放射疗法等）。

    Treatment of refractory cancers using Na+/K+-ATPase inhibitors
    6.
    发明申请
    Treatment of refractory cancers using Na+/K+-ATPase inhibitors 审中-公开
    使用Na + / K + -ATPase抑制剂治疗难治性癌症

    公开(公告)号：US20080027010A1

    公开(公告)日：2008-01-31

    申请号：US11653076

    申请日：2007-01-12

    申请人： Mehran Khodadoust ,  Ajay Sharma ,  Reimar Bruening

    发明人： Mehran Khodadoust ,  Ajay Sharma ,  Reimar Bruening

    IPC分类号： A61K31/57 ,  A61K31/704 ,  A61P35/00

    CPC分类号： A61K31/513 ,  A61K31/7072

    摘要： The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+/K+-ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.

    摘要翻译： 本发明的试剂，药物制剂，试剂盒和方法提供了使用Na + / K + + ATPase抑制剂如强心苷治疗难治性癌症的新方法， 包括bufadienolides或其相应的糖苷配基（例如proscillaridin，scillaren和scillarenin等），特别是含有超过1mg活性成分的口服制剂和/或固体剂型。

    Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
    7.
    发明申请
    Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors 审中-公开
    使用Na + / K + ATP酶抑制剂进行组合化疗

    公开(公告)号：US20070105789A1

    公开(公告)日：2007-05-10

    申请号：US11441396

    申请日：2006-05-24

    申请人： Mehran Khodadoust ,  Ajay Sharma ,  Reimar Bruening

    发明人： Mehran Khodadoust ,  Ajay Sharma ,  Reimar Bruening

    IPC分类号： A61K31/70 ,  A01N43/04

    CPC分类号： A61K45/06 ,  A61K31/585 ,  A61K2300/00

    摘要： The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells. The reagent and pharmaceutical formulation of the invention relates to Na+/K+-ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.

    摘要翻译： 本发明的试剂，药物制剂，试剂盒和方法提供了一种减轻或消除与使用某些癌症治疗剂（例如化疗治疗剂等）或方案（例如放射治疗等）相关的某些负面影响的新方法。 ），包括刺激肿瘤细胞中的低氧应激反应。 本发明的试剂和药物制剂涉及Na +，N +，N +， - ATP酶抑制剂，例如强心苷，包括蟾蜍糖苷或其相应的糖苷配基（例如，proscillaridin，scillaren ，和scillarenin等），特别是在含有超过1mg活性成分的口服制剂和/或固体剂型中。

    Human lipase proteins, nucleic acids encoding them, and uses of both of these
    8.
    发明授权
    Human lipase proteins, nucleic acids encoding them, and uses of both of these 失效
    人类脂肪酶蛋白，编码它们的核酸，以及这两者的用途

    公开(公告)号：US06558936B1

    公开(公告)日：2003-05-06

    申请号：US09411132

    申请日：1999-10-01

    申请人： Mehran Khodadoust ,  Rosana Kapeller-Libermann

    发明人： Mehran Khodadoust ,  Rosana Kapeller-Libermann

    IPC分类号： C12N920

    CPC分类号： C12N9/20 ,  A61K38/00 ,  A61K48/00 ,  C12Q1/6883

    摘要： The invention provides isolated nucleic acids encoding human lipase proteins and fragments, derivatives, and variants thereof. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders associated, for example, with aberrant lipid metabolism or aberrant pancreatic activity. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides, and antibodies. Diagnostic, prognostic, screening, and therapeutic methods involving use of compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes relating to mono-, di-, and triglyceride metabolism and pancreatic function.

    摘要翻译： 本发明提供编码人脂肪酶蛋白质的分离的核酸及其片段，衍生物和变体。 这些核酸和蛋白质可用于诊断，预防和治疗与例如异常脂质代谢或异常胰腺活动相关的许多人和其它动物疾病。 本发明还提供反义核酸分子，含有本发明的核酸分子的表达载体，已经引入了表达载体的宿主细胞和其中引入了本发明的核酸分子的非人转基因动物，或 中断了 本发明还进一步提供分离的多肽，融合多肽，抗原肽和抗体。 还提供了涉及使用本发明组合物的诊断，预后，筛选和治疗方法。 本发明的核酸和多肽可用作调节与甘油三酯，甘油三酯和甘油三酯代谢相关的各种细胞过程和胰腺功能的调节剂。

    MTbx protein and nucleic acid molecules and uses therefor
    9.
    发明授权
    MTbx protein and nucleic acid molecules and uses therefor 失效
    用于鉴定与mtbx多肽结合的结合物的方法

    公开(公告)号：US06291193B1

    公开(公告)日：2001-09-18

    申请号：US09514422

    申请日：2000-02-28

    申请人： Mehran Khodadoust

    发明人： Mehran Khodadoust

    IPC分类号： G01N3353

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2770/24222

    摘要： The present invention provides methods for identifying compounds that bind to MTBX, a novel cardiovascular system associated transcription factor regulatory polpeptide.

    摘要翻译： 本发明提供了用于鉴定与MTBX结合的化合物的方法，MTBX是新型心血管系统相关转录因子调节性多肽。

    Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
    10.
    发明申请
    Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors 审中-公开
    使用Na + / K + ATP酶抑制剂进行组合化疗

    公开(公告)号：US20060135441A1

    公开(公告)日：2006-06-22

    申请号：US11219636

    申请日：2005-09-02

    申请人： Mehran Khodadoust ,  Ajay Sharma

    发明人： Mehran Khodadoust ,  Ajay Sharma

    IPC分类号： A61K31/704

    CPC分类号： A61K45/06 ,  A61K31/585 ,  A61K2300/00

    摘要： The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells.

    摘要翻译： 本发明的试剂，药物制剂，试剂盒和方法提供了一种减轻或消除与使用某些癌症治疗剂（例如化疗治疗剂等）或方案（例如放射治疗等）相关的某些负面影响的新方法。 ），包括刺激肿瘤细胞中的低氧应激反应。